Fig. 1: Introduction of oncogenic PIK3CA mutation into hemangiosarcoma cells.
From: PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers
A Representative histopathological images from canine hemangiosarcoma and human angiosarcoma patients. H&E staining (left); immunohistochemistry with AKT antibody (middle) and phosphor-AKT antibody (right). B A homogeneous PIK3CA H1047R mutation was confirmed by Sanger sequencing analysis of the PIK3CA gene in wildtype (WT) and two different PIK3CA H1047R knock-in clones from DHSA-1426 hemangiosarcoma cells. C Representative live cell morphology was obtained by capturing bright field images at 20× (upper) and 10× (lower) magnifications. D Growth rates of the WT and PIK3CA-mutant cells were visualized by plotting the absolute cell numbers at days two, three, and four after seeding the same number of cells at day zero. E Genetic variation among three cells was assessed by analyzing the principal components of gene expression profiles obtained from bulk RNA-seq.
